The Novel A-Flux Coronary Sinus Reducer Normalizes Coronary Microvascular Function in a Persistently Symptomatic

Giovanni Occhipinti1, Anthony Salazar-Rodriguez1, Francesco Giannini2

  • 1Hospital Clínic, Cardiovascular Clinic Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.

JACC. Case Reports
|March 21, 2025
PubMed

Insights

Coronary microvascular dysfunction (CMD) causes chest pain and poor heart function. Coronary sinus reduction (CSR) using the A-Flux device may improve symptoms and blood flow in patients with CMD.

Area of Science:

  • Cardiology
  • Medical Devices
  • Vascular Biology

Background:

  • Coronary microvascular dysfunction (CMD) is a significant cause of angina and adverse cardiovascular outcomes.
  • Current treatments for CMD have limitations in improving symptoms and coronary blood flow.

Observation:

  • A patient diagnosed with coronary microvascular dysfunction (CMD) was treated with a novel device.
  • The intervention involved coronary sinus reduction (CSR) using the next-generation A-Flux device.

Findings:

  • The study reports on a patient undergoing CSR with the A-Flux device for CMD.
  • This intervention aims to alleviate symptom burden and enhance coronary flow reserve.

Implications:

  • Coronary sinus reduction (CSR) with advanced devices like A-Flux shows promise for managing CMD.
  • This approach may offer a new therapeutic strategy for patients with refractory angina due to CMD.